Rights issue in Biovitrum (SE) — SEK 1.5 billion

Carnegie acted as joint lead manager and underwriter to Biovitrum in a SEK 1.5 billion rights issue, to finance the consideration paid to the shareholders in Swedish Orphan in connection with the combination of Biovitrum and Swedish Orphan. The combination will result in a the creation of a new niche specialty pharmaceutical company focused on rare diseases with pro forma revenues 2009 of approximately SEK 2 billion and an EBITDA margin of 15 percent.January, 2010.